Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Larry Moreland to Receptors, Tumor Necrosis Factor

This is a "connection" page, showing publications Larry Moreland has written about Receptors, Tumor Necrosis Factor.

 
Connection Strength
  
 
 
3.738
  
  1. Moreland LW. Reply: The effect of triple therapy versus etanercept plus methotrexate in rheumatoid arthritis: comment on the article by Moreland et al. Arthritis Rheum. 2013 Feb; 65(2):539-40.
    View in: PubMed
    Score: 0.376
  2. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 2012 Sep; 64(9):2824-35.
    View in: PubMed
    Score: 0.365
  3. Moreland LW, Genovese MC, Sato R, Singh A. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis Rheum. 2006 Apr 15; 55(2):287-93.
    View in: PubMed
    Score: 0.235
  4. Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, Whitmore JB, White BW. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol. 2006 May; 33(5):854-61.
    View in: PubMed
    Score: 0.233
  5. Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol. 2002 Apr; 103(1):13-21.
    View in: PubMed
    Score: 0.177
  6. Moreland LW. Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritis. Isr Med Assoc J. 2001 Sep; 3(9):686-90.
    View in: PubMed
    Score: 0.170
  7. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, Weinblatt M, Taborn J, Weaver A, Burge DJ, Schiff MH. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol. 2001 Jun; 28(6):1238-44.
    View in: PubMed
    Score: 0.167
  8. Mikuls TR, Moreland LW. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Expert Opin Pharmacother. 2001 Jan; 2(1):75-84.
    View in: PubMed
    Score: 0.163
  9. Moreland LW, McCabe DP, Caldwell JR, Sack M, Weisman M, Henry G, Seely JE, Martin SW, Yee CL, Bendele AM, Frazier JL, Kohno T, Cosenza ME, Lyons SA, Dayer JM, Cohen AM, Edwards CK. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J Rheumatol. 2000 Mar; 27(3):601-9.
    View in: PubMed
    Score: 0.154
  10. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol Suppl. 1999 May; 57:7-15.
    View in: PubMed
    Score: 0.145
  11. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16; 130(6):478-86.
    View in: PubMed
    Score: 0.144
  12. Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis. 1999; 48(3):1-4.
    View in: PubMed
    Score: 0.142
  13. Moreland LW. Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am. 1998 Aug; 24(3):579-91.
    View in: PubMed
    Score: 0.138
  14. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997 Jul 17; 337(3):141-7.
    View in: PubMed
    Score: 0.128
  15. Moreland LW, Margolies G, Heck LW, Saway A, Blosch C, Hanna R, Koopman WJ. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol. 1996 Nov; 23(11):1849-55.
    View in: PubMed
    Score: 0.122
  16. Navarro-Millán I, Charles-Schoeman C, Yang S, Bathon JM, Bridges SL, Chen L, Cofield SS, Dell'Italia LJ, Moreland LW, O'Dell JR, Paulus HE, Curtis JR. Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. Arthritis Rheum. 2013 Jun; 65(6):1430-8.
    View in: PubMed
    Score: 0.096
  17. Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, Helfgott SM, Leff JA, Weinblatt ME. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol. 2006 Apr; 33(4):659-64.
    View in: PubMed
    Score: 0.058
  18. Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Genovese MC, White B, Singh A, Chon Y, Woolley JM. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies. Drugs Aging. 2006; 23(2):167-78.
    View in: PubMed
    Score: 0.058
  19. Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, Tsuji WH, Leff JA. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol. 2005 Jul; 32(7):1232-42.
    View in: PubMed
    Score: 0.056
  20. Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J Rheumatol. 2004 Aug; 31(8):1532-7.
    View in: PubMed
    Score: 0.052
  21. Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, Bekker P. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004 May; 50(5):1412-9.
    View in: PubMed
    Score: 0.051
  22. Fleischmann RM, Baumgartner SW, Tindall EA, Weaver AL, Moreland LW, Schiff MH, Martin RW, Spencer-Green GT. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol. 2003 Apr; 30(4):691-6.
    View in: PubMed
    Score: 0.048
  23. Misischia RJ, Moreland LW. Rheumatoid arthritis: developing pharmacological therapies. Expert Opin Investig Drugs. 2002 Jul; 11(7):927-35.
    View in: PubMed
    Score: 0.045
  24. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002 Jun; 46(6):1443-50.
    View in: PubMed
    Score: 0.045
  25. Hughes LB, Moreland LW. New therapeutic approaches to the management of rheumatoid arthritis. BioDrugs. 2001; 15(6):379-93.
    View in: PubMed
    Score: 0.041
  26. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30; 343(22):1586-93.
    View in: PubMed
    Score: 0.040
  27. Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther. 2000 Jan; 22(1):128-39.
    View in: PubMed
    Score: 0.038
  28. Mikuls T, Moreland L. The treatment of rheumatoid arthritis: a review of recent clinical trials. Curr Rheumatol Rep. 1999 Dec; 1(2):135-8.
    View in: PubMed
    Score: 0.038
  29. Moreland LW. Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun; 66(6):367-74.
    View in: PubMed
    Score: 0.036
  30. Koopman WJ, Moreland LW. Rheumatoid arthritis: anticytokine therapies on the horizon. Ann Intern Med. 1998 Feb 01; 128(3):231-3.
    View in: PubMed
    Score: 0.033
  31. O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL, Ranganath VK, Moreland LW. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum. 2013 Aug; 65(8):1985-94.
    View in: PubMed
    Score: 0.024
  32. Curtis JR, McVie T, Mikuls TR, Reynolds RJ, Navarro-Millán I, O'Dell J, Moreland LW, Bridges SL, Ranganath VK, Cofield SS. Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: results from the TEAR Trial. J Rheumatol. 2013 May; 40(5):572-8.
    View in: PubMed
    Score: 0.024
  33. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedrén S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak PP, Crusius JB, van der Horst-Bruinsma IE, Wolbink GJ, van Riel PL, van de Laar M, Guchelaar HJ, Shadick NA, Allaart CF, Huizinga TW, Toes RE, Kimberly RP, Bridges SL, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJ, Karlson EW, Plenge RM. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013 Mar; 9(3):e1003394.
    View in: PubMed
    Score: 0.024
  34. Maska LB, Sayles HR, O'Dell JR, Curtis JR, Bridges SL, Moreland LW, Cofield SS, Mikuls TR. Serum cotinine as a biomarker of tobacco exposure and the association with treatment response in early rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 Dec; 64(12):1804-10.
    View in: PubMed
    Score: 0.023
  35. Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL. Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec; 5(8):641-7.
    View in: PubMed
    Score: 0.013
  36. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep; 50(9):2750-6.
    View in: PubMed
    Score: 0.013
  37. Shanahan JC, Moreland LW, Carter RH. Upcoming biologic agents for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2003 May; 15(3):226-36.
    View in: PubMed
    Score: 0.012
  38. Hughes LB, Moreland LW, Bridges SL. Genetic influences on rheumatoid arthritis in African Americans. Immunol Res. 2002; 26(1-3):15-26.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)